Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection. ABSTRACT Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
【저자키워드】 COVID-19, Endothelial dysfunction, generic drugs, host response treatment, 【초록키워드】 ACE2, ARDS, Trial, Infection, risk, clinical, Patient, death, receptor, angiotensin, acute respiratory disease, Severe COVID-19 Infection, tissue, drug combination, syndrome, treat, blocker, PROTECT, determine, with COVID-19, 【제목키워드】 treating,